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4) Development of an indirect ELISA-GFP assay 
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Serological interference in diagnostic tests is a major problem associated to the use of veterinary vaccines, which hamper the differentiation of infected and 
vaccinated animals (DIVA). To solve this problem in the context of brucellosis, our group is developing new Brucella vaccines tagged with green fluorescent 
protein (GFP) as xenogenic marker to be used in combination with associated DIVA diagnostic tests. 
The aim of this work was to develop Gel Diffusion (GD-GFP) and indirect-ELISA (ELISA-GFP) assays able to detect specifically anti-GFP antibodies in sheep. 
Total dose: 200 Pg GFP/sheep in IFA (1:1): 
 GFP + IFA; GFP-GST + IFA; IFA control 
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All hyperimmunized sera showed  
antibodies against both proteins  
Parameters analysed:  
 
1. E.coli XL1-Blue with pGEX-4T-1-gfpmut3 expression system allows to obtain 
GFP-GST from soluble fraction in purity, antigenicity and amount appropriate 
to be used in serological diagnostic test. 
 
2. Both GFP-GST and GFP as antigens allow to detect especific anti-GFP 
antibodies in sheep sera, in GD-GFP test. 
 
3. The selected ELISA-GFP conditions allowed a 99% of diagnostic specificity 
with sheep sera. Further analysis with sera from Brucella-GFP vaccinated 
sheep are necessary to assess the final value of this serological test. 
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 Optimal concentration of antigen: 
31.25 µg/mL of GFP for GFP-GST and GFP 
Antigen selection: GFP-GST performed better than GFP in standard conditions (PBST fixation) 
Effect of ABTS incubation and milk blocking: 
Conditions that allowed the best discrimination 
(doted red lines) between positive and negative 
sera were:   
  - Milk blocking 
  - 1:4000 conjugate dilution 
  - 1:100 serum dilution and 15’ or 30’ ABTS 
incubation; or 1:200 serum dilution and 30’ 
ABTS incubation 
Diagnostic Specificity: The selected ELISA-GFP 
conditions resulted in 99 % specificity 
Both proteins were obtained in amount (500 
µg/mL), purity and antigenicity expected 
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